Risk management of biosimilars in oncology: each medicine is a work in progress.
about
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal AntibodiesBiosimilars: the need, the challenge, the future: the FDA perspectiveBiosimilars: Hope and concern.Improving Access to Cancer Treatments: The Role of Biosimilars.Biologicals and biosimilars: safety issues in Europe.The process defines the product: what really matters in biosimilar design and production?
P2860
Risk management of biosimilars in oncology: each medicine is a work in progress.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Risk management of biosimilars in oncology: each medicine is a work in progress.
@ast
Risk management of biosimilars in oncology: each medicine is a work in progress.
@en
type
label
Risk management of biosimilars in oncology: each medicine is a work in progress.
@ast
Risk management of biosimilars in oncology: each medicine is a work in progress.
@en
prefLabel
Risk management of biosimilars in oncology: each medicine is a work in progress.
@ast
Risk management of biosimilars in oncology: each medicine is a work in progress.
@en
P2860
P1433
P1476
Risk management of biosimilars in oncology: each medicine is a work in progress.
@en
P2093
Arnold G Vulto
Stacy A Crow
P2860
P2888
P356
10.1007/S11523-011-0188-3
P478
P577
2012-01-25T00:00:00Z